Search Results - "Yulius, Y"

In vivo depletion of CD4⁺FOXP3⁺ Treg cells by the PC61 anti-CD25 monoclonal antibody is mediated by FcγRIII⁺ phagocytes by Setiady, Yulius Y, Coccia, Jennifer A, Park, Peter U

“…Depletion of CD4⁺CD25⁺FoxP3⁺ Treg using PC61 mAb (anti-murine CD25 rat IgG1) is widely used to characterize Treg function in vivo. However, the mechanism of…”
Get full text

Function-Blocking ERBB3 Antibody Inhibits the Adaptive Response to RAF Inhibitor by KUGEL, Curtis H, HARTSOUGH, Edward J, DAVIES, Michael A, SETIADY, Yulius Y, APLIN, Andrew E

“…ERBB3/HER3 expression and signaling are upregulated in mutant BRAF melanoma as an adaptive, prosurvival response to FDA-approved RAF inhibitors. Because…”
Get full text

Evaluation of Targets for Maytansinoid ADC Therapy Using a Novel Radiochemical Assay by Lai, Katharine C., Deckert, Jutta, Setiady, Yulius Y., Shah, Prerak, Wang, Lintao, Chari, Ravi, Lambert, John M.

“…Purpose Many antibody-drug conjugates (ADCs) become active only after antigen-mediated internalization and release of the cytotoxic agent via antibody…”
Get full text

A New Triglycyl Peptide Linker for Antibody-Drug Conjugates (ADCs) with Improved Targeted Killing of Cancer Cells by Singh, Rajeeva, Setiady, Yulius Y, Ponte, Jose, Kovtun, Yelena V, Lai, Katharine C, Hong, E Erica, Fishkin, Nathan, Dong, Ling, Jones, Gregory E, Coccia, Jennifer A, Lanieri, Leanne, Veale, Karen, Costoplus, Juliet A, Skaletskaya, Anna, Gabriel, Rabih, Salomon, Paulin, Wu, Rui, Qiu, Qifeng, Erickson, Hans K, Lambert, John M, Chari, Ravi V J, Widdison, Wayne C

“…A triglycyl peptide linker (CX) was designed for use in antibody -: drug conjugates (ADC), aiming to provide efficient release and lysosomal efflux of…”
Get full text

ErbB3-ErbB2 Complexes as a Therapeutic Target in a Subset of Wild-type BRAF/NRAS Cutaneous Melanomas by Capparelli, Claudia, Rosenbaum, Sheera, Berman-Booty, Lisa D, Salhi, Amel, Gaborit, Nadège, Zhan, Tingting, Chervoneva, Inna, Roszik, Jason, Woodman, Scott E, Davies, Michael A, Setiady, Yulius Y, Osman, Iman, Yarden, Yosef, Aplin, Andrew E

“…The treatment options remain limited for patients with melanoma who are wild-type for both BRAF and NRAS (WT/WT). We demonstrate that a subgroup of WT/WT…”
Get full text

The role of physiological self-antigen in the acquisition and maintenance of regulatory T-cell function by Samy, Eileen T., Setiady, Yulius Y., Ohno, Katsuhiro, Pramoonjago, Patcharin, Sharp, Colin, Tung, Kenneth S. K.

“…The CD4+CD25+ regulatory T cells (Tregs) are efficient regulators of autoimmunity, but the mechanism remains elusive. We summarize recent data for the…”
Get full text

Analisis Sistem Informasi Geografis (SIG) untuk Potensi Wisata Pantai di Kota Makasar, Provinsi Sulawesi Selatan by Yulius, Y, Arifin, Taslim

“…Makassar city, as a capital of South Sulawesi Province, has potential natural resources with its moderately sloped sandy beach, from north to south. The aims…”
Get full text

Physiologic self antigens rapidly capacitate autoimmune disease-specific polyclonal CD4+CD25+ regulatory T cells by Setiady, Yulius Y., Ohno, Katsuhiro, Samy, Eileen T., Bagavant, Harini, Qiao, Hui, Sharp, Colin, She, Jin Xiong, Tung, Kenneth S.K.

“…Studies on CD4+CD25+ regulatory T cells (Tregs) with transgenic T-cell receptors indicate that Tregs may receive continuous antigen (Ag) stimulation in the…”
Get full text

Respons psikososial dan kesejahteraan psikologis pasien filariasis di Kota Ambon by Reasoa, Melany S., Ranimpi, Yulius Y., Kurniasari, R. Rr. Maria D., De Fretes, Fiane

“…Filariasis (kaki gajah) merupakan penyakit tropis yang sangat umum terjadi di beberapa daerah di Indonesia. Filariasis disebabkan oleh penularan mikroorganisme…”
Get full text

Maternal Autoantibody Triggers De Novo T Cell-Mediated Neonatal Autoimmune Disease by Setiady, Yulius Y, Samy, Eileen T, Tung, Kenneth S. K

“…Although human maternal autoantibodies may transfer transient manifestation of autoimmune disease to their progeny, some neonatal autoimmune diseases can…”
Get full text

Requirements of NK Cells and Proinflammatory Cytokines in T Cell-Dependent Neonatal Autoimmune Ovarian Disease Triggered by Immune Complex by Setiady, Yulius Y, Pramoonjago, Patcharin, Tung, Kenneth S. K

“…A model of neonatal autoimmune disease has been described recently in which an epitope-specific autoantibody to murine zona pellucida 3 induces severe ovarian…”
Get full text

Expression library immunization protects mice against a challenge with virulent rodent malaria by Smooker, Peter M, Setiady, Yulius Y, Rainczuk, Adam, Spithill, Terry W

“…Although several candidate vaccine antigens have been developed for malaria, there is as yet no effective single vaccine available. There is a growing…”
Get full text

Neonatal Autoimmune Disease: Influence of CD4+ CD25+ Regulatory T Cells by Setiady, Yulius Y., Agersborg, Sally, Samy, Eileen T., Lewis, Janet E., Tung, Kenneth S. K.

“…Although previous studies have emphasized the tolerogenic property of murine neonatal immune system, recent studies indicate that neonatal mice are prone to…”
Get full text

Abstract 4513: IMGN289, an EGFR-targeting antibody-drug conjugate, is effective against tumor cells that are resistant to EGFR tyrosine kinase inhibitors by Setiady, Yulius Y., Dong, Ling, Skaletskaya, Anna, Pinkas, Jan, Lutz, Robert J., Lambert, John M., Chittenden, Thomas

“…EGFR is one of the oncogenic drivers in non-small-cell lung adenocarcinoma (NSCLC AC). EGFR tyrosine kinase inhibitors (TKIs), such as erlotinib, gefitinib and…”
Get full text

Abstract A09: ErbB3/ErbB2 complexes as a therapeutic target in a subset of wild-type BRAF/NRAS cutaneous melanomas by Capparelli, Claudia, Rosenbaum, Sheera, Berman-Booty, Lisa D., Gaborit, Nadège, Zhan, Tingting, Davies, Michael A., Setiady, Yulius Y., Yarden, Yosef, Aplin, Andrew E.

“…The treatment options remain poor for melanoma patients who are wild-type for both BRAF and NRAS (WT/WT). ErbB3 regulates melanocyte homeostasis and elevated…”
Get full text

Abstract A52: Extracellular matrix regulation of ErbB3 in a subset of wild-type BRAF/NRAS melanoma by Rosenbaum, Sheera, Capparelli, Claudia, Berman-Booty, Lisa D., Gaborit, Nadège, Zhan, Tingting, Davies, Michael A., Setiady, Yulius Y., Yarden, Yosef, Aplin, Andrew E.

“…While the incidence of melanoma increases each year, treatment options for melanoma patients wild-type for both BRAF and NRAS (WT-WT) remain limited. The tumor…”
Get full text

Abstract 5483: Preclinical evaluation of IMGN289, an anti-EGFR antibody-maytansinoid conjugate for the treatment of squamous cell carcinoma of the head and neck by Ponte, Jose F., Setiady, Yulius Y., Dong, Ling, Skaletskaya, Anna, Carrigan, Christina N., Anderson-Villaluz, Alfred, Lutz, Robert J., Pinkas, Jan

“…Squamous cell carcinoma of the head and neck (SCCHN) include cancers that affect the squamous epithelium of the mouth, larynx, nasal passages, sinuses and…”
Get full text

Abstract 770: Lorvotuzumab mertansine (IMGN901) immune effector activity and its effect on human NK cells by Skaletskaya, Anna, Setiady, Yulius Y., Park, Peter U., Lutz, Robert J.

“…Lorvotuzumab mertansine, or IMGN901, is a conjugate consisting of the cytotoxic maytansinoid, DM1, covalently linked to the monoclonal antibody, lorvotuzumab,…”
Get full text

Abstract 5463: Development of a novel antibody-maytansinoid conjugate, IMGN289, for the treatment of EGFR-expressing solid tumors by Setiady, Yulius Y., Park, Peter U., Ponte, Jose F., Dong, Ling, Skaletskaya, Anna, Coccia, Jennifer A., Hong, Erica, Clancy, Lauren, Rui, Lingyun, Pinkas, Jan, Lutz, Robert J., Lambert, John M., Chittenden, Thomas D.

“…EGFR is an attractive target for the treatment of a variety of solid tumors because of its role as a driver oncogene and high level of expression. Four…”
Get full text

Abstract 5467: IMGN289, an EGFR-targeting antibody-maytansinoid conjugate with potent activity against non-small cell lung cancer (NSCLC) regardless of dependency on EGFR pathway by Chittenden, Thomas D., Setiady, Yulius Y., Park, Peter U., Ponte, Jose F., Dong, Ling, Skaletskaya, Anna, Carrigan, Christina N., Villaluz, Alfred A., Pinkas, Jan, Lutz, Robert J., Lambert, John M.

“…NSCLC accounts for approximately 85% of all lung cancers. Based on tumor histology, NSCLC can be subdivided into adenocarcinoma (AC), squamous cell carcinoma…”
Get full text